Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
CA 2443886 A1 · Owner: Koning, Frits · Inventors: Drijfhout, Jan Wouter; Sollid, Ludvig Magne; Mcadam, Stephan Neil
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides an isolated or recombinant HLA-DQ restricted Tcell receptor or functional equivalent and/or fragment thereof capable of recognizing a prolamine-derived peptide. The present invention also provides isolated, recombinant or synthetic prolamine-derived peptides involved in foodrelated immune enteropathy. In yet another embodiment the invention provides a diagnostic kit comprising an isolated or recombinant HLA-DQ restricted T-cell receptor according to the invention or host cell comprising a T-cell receptor according to the invention or an antibody according to the invention and a suitable means of detection. Such a diagnostic kit is for example, very , …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 11, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 11, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 11, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.